[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Epiomic Epidemiology Series: Retinal Vein Occlusion Forecast in 8 Major Markets 2015-2025

August 2015 | 40 pages | ID: E3DD827D814EN
Black Swan Analysis limited

US$ 6,382.00

E-mail Delivery (PDF), Hard Copy Mail Delivery

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Retinal Vein Occlusion (RVO) is a common vascular disorder of the retina and one of the most common causes of vision loss worldwide. It is caused by the blockage of a portion of the venous circulation that drains the retina and can result in haemorrhage and fluid loss. This report provides the current prevalent population for RVO across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the types, occlusion locations and the prevalence of associated disorders of RVO. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of RVO have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for RVO include:
  • Visual complications
  • Blindness
  • Cardiovascular diseases
  • Diabetes mellitus
  • Hypertension
  • Glaucoma
  • Dense Muscular haemorrhage
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy
  • Able to quantify patient populations in global RVO’s market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of RVO and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on RVO’s prevalent population.
  • Identify sub-populations within RVO which require treatment.
  • Gain an understanding of the specific markets that have the largest number of RVO patients.
Overview
Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis &Clinical Course
Key Comorbid Conditions/Features Associated with the Disease
Methodology for Quantification of Patient Numbers
Top-Line RVO Prevalence
Main Type of RVO
Occlusion location of RVO
Central RVO
  Co-morbidities within CRVO
Branch RVO
  Co-morbidities within BRVO
References
Appendix

LIST OF TABLES & FIGURES

Prevalence of RVO, total (000s)
Prevalence of RVO, males (000s)
Prevalence of RVO, females (000s)
RVO by vein affected, total (000s)
Main occlusion location for RVO, total (000s)
Prevalence of CRVO by main aetiology, total (000s)
Glaucoma by type within CRVO, total (000s)
Prevalence of Diabetes in CRVO, total (000s)
Prevalence of Hypertension in CRVO, total (000s)
Prevalence of BRVO by main type, total (000s)
Macular status at diagnosis of BRVO, total (000s)
Glaucoma by type within BRVO, total (000s)
Prevalence of Diabetes in BRVO, total (000s)
Prevalence of Hypertension in BRVO, total (000s)
Prevalence of Dense macular haemorrhage in BRVO, total (000s)
USA Prevalence of RVO by 5-yr age cohort, males (000s)
USA Prevalence of RVO by 5-yr age cohort, females (000s)
France Prevalence of RVO by 5-yr age cohort, males (000s)
France Prevalence of RVO by 5-yr age cohort, females (000s)
Germany Prevalence of RVO by 5-yr age cohort, males (000s)
Germany Prevalence of RVO by 5-yr age cohort, females (000s)
Italy Prevalence of RVO by 5-yr age cohort, males (000s)
Italy Prevalence of RVO by 5-yr age cohort, females (000s)
Spain Prevalence of RVO by 5-yr age cohort, males (000s)
Spain Prevalence of RVO by 5-yr age cohort, females (000s)
United Kingdom Prevalence of RVO by 5-yr age cohort, males (000s)
United Kingdom Prevalence of RVO by 5-yr age cohort, females (000s)
Brazil Prevalence of RVO by 5-yr age cohort, males (000s)
Brazil Prevalence of RVO by 5-yr age cohort, females (000s)
Japan Prevalence of RVO by 5-yr age cohort, males (000s)
Japan Prevalence of RVO by 5-yr age cohort, females (000s)


More Publications